Wir sind mit live! Mehr erfahren

Medpace

MEDP

Börsenwert 17,3 Mrd. $

618,47 USD

-10,13

1,61 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

618,47

0,00

0 %

1 Tag

-1,61 %

5 Tage

0,94 %

1 Monat

0,33 %

3 Monate

14,97 %

6 Monate

19,94 %

Seit Jahresbeginn

8,31 %

1 Jahr

18,66 %

5 Jahre

232,83 %

10 Jahre

1.996,51 %

Profil: Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Mitarbeiter: 6.500

Gesundheitswesen Diagnostik & Research

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 70,6 %

Neutral 29,4 %

Negativ 0 %

Zacks Investment Research

CON vs. MEDP: Which Stock Should Value Investors Buy Now?

Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?

CON vs. MEDP: Which Stock Should Value Investors Buy Now?

Zacks Investment Research

Medpace (MEDP) Dips More Than Broader Market: What You Should Know

In the latest trading session, Medpace (MEDP) closed at $609.89, marking a -1.64% move from the previous day.

Medpace (MEDP) Dips More Than Broader Market: What You Should Know

Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One

Medpace Holdings is misunderstood due to its faster, cleaner backlog burn, which the market misinterprets as a growth ceiling rather than a quality upgrade. Q2 revenues rose 17.2% to $707.3M, with EBITDA margin improving beneath headline pass-through cost effects; guidance for FY26 was raised across revenue, EBITDA, and EPS. Customer prepayments fund operations and share buybacks, supporting EPS growth and providing a buffer against potential cash flow volatility as biotech funding rebounds.

Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One

Zacks Investment Research

Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

Medpace (MEDP) concluded the recent trading session at $602.9, signifying a -2.84% move from its prior day's close.

Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

Zacks Investment Research

Medpace (MEDP) Rises As Market Takes a Dip: Key Facts

In the closing of the recent trading day, Medpace (MEDP) stood at $622.11, denoting a +1% move from the preceding trading day.

Medpace (MEDP) Rises As Market Takes a Dip: Key Facts

Zacks Investment Research

CON or MEDP: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?

CON or MEDP: Which Is the Better Value Stock Right Now?

Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Company will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended yo.

Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026

Zacks Investment Research

Medpace (MEDP) Outperforms Broader Market: What You Need to Know

Medpace (MEDP) concluded the recent trading session at $624.2, signifying a +1.94% move from its prior day's close.

Medpace (MEDP) Outperforms Broader Market: What You Need to Know

Zacks Investment Research

Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

In the latest trading session, Medpace (MEDP) closed at $595.41, marking a +1.34% move from the previous day.

Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

Zacks Investment Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks is more attractive to value investors?

CON vs. MEDP: Which Stock Is the Better Value Option?

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt